Description
Created On: 2020-07-15
Record Count: 4
Primary Industries
- Drugs
- Antibiotic
- Diagnostic
- Therapeutic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 268565
antiinfective drug targets and rational drug design.
Licensor grants:
— a worldwide, non-exclusive license, with the right to sublicense, under the Licensor Technology solely to perform Research in the Field with respect to Proposed Targets, Medicinal Chemistry Programs, Shared Programs and Licensee Programs during the Research Term;
— a worldwide, exclusive license, with the right to sublicense, under the Licensor Technology to develop, make, have made, use, sell, have sold, offer for sale and import Licensee Products in the Field; and
— a worldwide, non-exclusive license, with the right to sublicense, under the Licensor Technology to develop, make, have made, use, sell, have sold, offer for sale and import Independent Products in the Field.
Product shall mean a Shared Product, Licensee Product, Licensor Product or Independent Product.
Pharmacophore shall mean the minimum chemical structure that provides the basis for activity of a compound against a Gene Target.
IPSCIO Record ID: 266779
antiinfective drug targets and rational drug design.
Licensor grants:
— a worldwide, non-exclusive license, with the right to sublicense, under the Licensor Technology solely to perform Research in the Field with respect to Proposed Targets, Medicinal Chemistry Programs, Shared Programs and Cubist Programs during the Research Term;
— a worldwide, exclusive license, with the right to sublicense, under the Licensor Technology to perform development activities for Shared Programs after designation of IND Candidates for such Shared Programs, to develop Licensee Products, and to make, have made, use, sell, have sold, offer for sale and import Shared Products and Licensee Products in the Field; and
— a worldwide, non-exclusive license, with the right to sublicense, under the Licensor Technology to develop, make, have made, use, sell, have sold, offer for sale and import Independent Products in the Field.
Product shall mean a Shared Product, Licensee Product, Licensor Product or Independent Product.
Pharmacophore shall mean the minimum chemical structure that provides the basis for activity of a compound against a Gene Target.
IPSCIO Record ID: 266778
Licensees Product means either a Licensor Derivative Product which is a product for the making, using, selling, offering for sale, or import of which would, but for the licenses granted herein, infringe a valid claim of a Research Patent or that includes a Licensor Derivative; or Licensee Derivative Product which is a product containing a Licensee Derivative.
Licensor Derivative means a compound(s) prepared by Licensor pursuant to the Research Program and that is either a derivative of daptomycin created utilizing synthesis or biocatalysis technology developed or practiced by Licensor, or a derivative of any such derivative created utilizing synthesis or biocatalysis technology developed or practiced by Licensor, and/or compound(s) prepared by Licensee or its Affiliates or Sublicensees that are simple esters or salts of compounds.
Biocatalytic process means biocatalytic procedure or biocatalysis used by Licensor to prepare derivatives of daptomycin and, without limitation, any process or procedure using organisms, catalysts, whether whole cell or isolated enzyme-based, strains, vectors, proprietary catalyst preparation procedures, aqueous buffers or organic solvents, modifiers and enzyme cofactors.
Licensor will use its proprietary combinatorial biocatalysis technology to create derivatives of lipopeptides, a novel class of anti-infectives. And Licensee is currently developing Cidecin® (daptomycin for injection)–the first investigational antibiotic derived from this new class.
IPSCIO Record ID: 148591
Party established a collaboration to utilize bacterial genetic approaches with in vitro essential genes to discover products for the treatment of bacterial infections in animals.
